Lmr Partners LLP Intra Cellular Therapies, Inc. Transaction History

Lmr Partners LLP

$10.9 Billion
Q3 2024

A detailed history of Lmr Partners LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 31,177 shares of ITCI stock, worth $2.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

31,177

Previous 33,289 6.34%

Holding current value

$2.6 Million

Previous $2.28 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$67.99 - $80.84 $143,594 - $170,734	-2,112 Reduced 6.34%	31,177 $2.28 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $798,426 - $984,347	12,329 Added 58.82%	33,289 $2.28 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $1.35 Million - $1.59 Million	20,960 New	20,960 $1.45 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $244,823 - $301,270	4,700 New	4,700 $244,000
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $322,500 - $492,300	-7,500 Reduced 48.7%	7,900 $451,000
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $596,596 - $956,186	15,400 New	15,400 $942,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $422,400 - $641,040	-12,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $344,640 - $509,880	12,000 New	12,000 $447,000
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $717,500 - $1.33 Million	-50,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $615,500 - $1.66 Million	-50,000 Reduced 50.0%	50,000 $791,000
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $726,000 - $3.85 Million	100,000 New	100,000 $3.43 Million

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.87B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account